Education
About Us
Working with TipRanks
Follow Us
iTeos Therapeutics (ITOS)
NASDAQ:ITOS
Total Valuation
iTeos Therapeutics has a market cap or net worth of $253.37M. The enterprise value is -$257.17M.
Market Cap$253.37M
Enterprise Value-$257.17M
Share Statistics
iTeos Therapeutics has 38,273,796 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding38,273,796
Owned by Insiders23.82%
Owned by Institutions<0.01%
Financial Efficiency
iTeos Therapeutics’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -27.50%.
Return on Equity (ROE)-0.23
Return on Assets (ROA)-0.20
Return on Invested Capital (ROIC)-27.50%
Return on Capital Employed (ROCE)-0.25
Revenue Per Employee202.31K
Profits Per Employee-776.96K
Employee Count173
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of iTeos Therapeutics is -2.31. iTeos Therapeutics’s PEG ratio is -0.43.
PE Ratio-2.31
PS Ratio0.00
PB Ratio0.53
Price to Fair Value0.53
Price to FCF-3.11
Price to Operating Cash Flow-3.17
PEG Ratio-0.43
Income Statement
In the last 12 months, iTeos Therapeutics had revenue of 35.00M and earned -134.41M in profits. Earnings per share was -3.32.
Revenue35.00M
Gross Profit33.76M
Operating Income-159.53M
Pretax Income-120.34M
Net Income-134.41M
EBITDA-159.53M
Earnings Per Share (EPS)-3.32
Cash Flow
In the last 12 months, operating cash flow was -99.55M and capital expenditures -789.00K, giving a free cash flow of -100.33M billion.
Operating Cash Flow-99.55M
Free Cash Flow-100.33M
Free Cash Flow per Share-2.62
Dividends & Yields
iTeos Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.57
52-Week Price Change-47.21%
50-Day Moving Average6.65
200-Day Moving Average9.57
Relative Strength Index (RSI)46.10
Average Volume (3m)477.42K
Important Dates
iTeos Therapeutics upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateApr 28, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
iTeos Therapeutics as a current ratio of 12.62, with Debt / Equity ratio of 0.90%
Current Ratio12.62
Quick Ratio12.62
Debt to Market Cap<0.01
Net Debt to EBITDA0.86
Interest Coverage Ratio0.00
Taxes
In the past 12 months, iTeos Therapeutics has paid 14.07M in taxes.
Income Tax14.07M
Effective Tax Rate-0.12
Enterprise Valuation
iTeos Therapeutics EV to EBITDA ratio is -1.09, with an EV/FCF ratio of -1.74.
EV to Sales4.97
EV to EBITDA-1.09
EV to Free Cash Flow-1.74
EV to Operating Cash Flow-1.77
Balance Sheet
iTeos Therapeutics has $520.37M in cash and marketable securities with $5.82M in debt, giving a net cash position of -$515.32M billion.
Cash & Marketable Securities$520.37M
Total Debt$5.82M
Net Cash-$515.32M
Net Cash Per Share-$13.46
Tangible Book Value Per Share$14.58
Margins
Gross margin is 99.12%, with operating margin of -455.79%, and net profit margin of -384.04%.
Gross Margin99.12%
Operating Margin-455.79%
Pretax Margin-343.83%
Net Profit Margin-384.04%
EBITDA Margin-455.79%
EBIT Margin-440.93%
Analyst Forecast
The average price target for iTeos Therapeutics is $23.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$23.00
Price Target Upside257.14% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast14.60%